Skip to main content

Live Aurinia Pharmaceuticals Inc Share Price Chart

O 15.065H 15.065L 15.04

Aurinia Pharmaceuticals Inc Performance Overview

Days Range
▼
$14.83Low
$15.06High

Markets Today

Previous Close$15.13
Open$15.06
Volume490,872
Day's Range$14.83 - $15.06
52W Range$13.52 - $19.25
Market Cap$2.03 B

Historical Performance

1M Returns-11.05
3M Returns-13.78
6M Returns-6.35
1Y Returns-1.65
5Y Returns-47.70
10Y Returns+325.43

Aurinia Pharmaceuticals Inc Fundamentals

Market Cap$2.03 B
Dividend yield0.00
PE Ratio7.07
PEG RatioN/A
Revenue$283.06 M
ROE TTM0.60
EPS TTM$2.29
Quarterly Earnings Growth YOYN/A
PB Ratio3.30
EBITDA$126.01 M
Profit Margin101.47
Market Cap$2.03 B
Dividend yield0.00
PE Ratio7.07
PEG RatioN/A
Revenue$283.06 M
ROE TTM0.60
EPS TTM$2.29
Quarterly Earnings Growth YOYN/A
PB Ratio3.30
EBITDA$126.01 M
Profit Margin101.47

Aurinia Pharmaceuticals Inc Profit & Loss

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Total Revenue +$70.01 M$73.47 M$77.11 M$77.70 M$83.22 M$83.70 M
Gross Profit +$62.89 M$65.29 M$68.31 M$71.20 M$76.67 M$75.39 M
Operating Income $20.08 M$29.75 M$18.64 M$41.42 M$46.34 M$35.36 M
EBITDA $25.06 M$34.61 M$23.50 M$46.24 M$51.17 M$40.20 M
Interest Expense -$1.12 M-$1.10 M-$1.05 M-$1.01 M-$948.00 K-$867.00 K
Depreciation $4.98 M$4.87 M$4.86 M$4.82 M$4.83 M$4.84 M
Income Before Tax $22.16 M$31.96 M$35.69 M$43.92 M$48.79 M$38.72 M
Income Tax Expense $643.00 K$411.00 K-$175.10 M$9.57 M$11.37 M$7.01 M
Net Income +$21.51 M$31.55 M$210.79 M$34.35 M$37.41 M$31.70 M
Net Profit Margin 30.73%42.95%273.35%44.21%44.96%37.88%

Aurinia Pharmaceuticals Inc Financials Balance Sheet In USD

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Share Capital $1.12 B$1.12 B$1.12 B$1.09 B$1.12 B$1.13 B
Reserve & Surplus -$892.62 M-$860.91 M-$649.97 M-$615.89 M-$578.58 M-$547.03 M
Non-Current Liabilities $89.00 M$85.54 M$76.53 M$69.81 M$77.50 M$72.18 M
Current Liabilities $78.27 M$76.22 M$93.72 M$86.56 M$99.89 M$96.00 M
Total Liabilities $167.26 M$161.76 M$170.26 M$156.37 M$177.40 M$168.19 M
Fixed Assets $6.47 M$6.17 M$5.87 M$5.58 M$5.24 M$4.91 M
Current Assets $408.97 M$438.74 M$491.97 M$480.24 M$541.32 M$587.89 M
Total Assets $502.56 M$527.53 M$751.59 M$724.00 M$792.26 M$825.70 M

Aurinia Pharmaceuticals Inc Cash Flow

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Net Income $21.51 M$31.55 M$210.79 M$34.35 M$37.41 M$31.70 M
Operating Cash Flow $44.24 M$44.45 M$45.67 M$32.56 M$52.57 M$46.37 M
Investing Cash Flow -$13.27 M-$13.77 M-$36.76 M-$18.08 M$81.45 M-$175.73 M
Financing Cash Flow -$44.39 M-$10.49 M-$1.89 M-$53.69 M$4.81 M-$4.32 M
Change in Cash -$13.43 M$20.19 M$7.02 M-$39.20 M$138.82 M-$133.69 M

Aurinia Pharmaceuticals Inc Return Calculator

The Aurinia Pharmaceuticals Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Returns Estimator

Based on past performance of this fund

ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$5,205
Invested Amount$10,000
Est. Returns$-4,795
Invest in USA Stock Today

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

FAQs

Aurinia Pharmaceuticals Inc (AUPH) share price as of November 20, 2026 is $14.82. If you are investing from India, you can always check the valuation in the INR before investing.
Yes, Indian Investors can invest in the Aurinia Pharmaceuticals Inc (AUPH) Share by opening an international trading account with Angel One.
Purchasing Aurinia Pharmaceuticals Inc (AUPH) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying Aurinia Pharmaceuticals Inc (AUPH) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Yes, you can purchase fractional shares of Aurinia Pharmaceuticals Inc (AUPH) or any other US company shares in Angel One for any dollar amount.
The market capitalization of Aurinia Pharmaceuticals Inc on November 20, 2026, is $2.03 B.
Aurinia Pharmaceuticals Inc operates in the Healthcare sector, specifically in the Healthcare industry.
In order to invest in Aurinia Pharmaceuticals Inc (AUPH) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.